Chemomab Therapeutics (CMMB) Gains from Investment Securities (2017 - 2021)
Chemomab Therapeutics posted quarterly Gains from Investment Securities of $17.8 million for Q4 2021, up 8210.58% year-on-year from $214000.0 in Q4 2020, and up 8210.58% on a QoQ basis from $214000.0 in Q4 2020.
Chemomab Therapeutics (CMMB) has 5 years of Gains from Investment Securities data on file, last reported at $17.8 million in Q4 2021.
- For the quarter ending Q4 2021, Gains from Investment Securities rose 8210.58% year-over-year to $17.8 million; the trailing twelve-month figure through Dec 2021 stood at $17.8 million (up 2037.32% YoY), and the FY2023 full-year result was $392000.0, up 2205.88% from the prior year.
- Gains from Investment Securities for Q4 2021 stood at $17.8 million, up from $214000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $17.8 million in Q4 2021 and bottomed at -$975000.0 in Q4 2019.
- The 5-year median for Gains from Investment Securities is $453048.0 (2018), against an average of $2.6 million.
- The widest annual swing landed in 2019, when Gains from Investment Securities tumbled 299.8%; it then jumped 8210.58% in 2021.
- A 5-year view of Gains from Investment Securities shows it stood at $1.2 million in 2017, then slumped by 60.02% to $488000.0 in 2018, then sank by 299.8% to -$975000.0 in 2019, then jumped by 121.95% to $214000.0 in 2020, then surged by 8210.58% to $17.8 million in 2021.
- The last three Gains from Investment Securities figures came in at $17.8 million (Q4 2021), $214000.0 (Q4 2020), and $3.1 million (Q3 2020), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Chemomab Therapeutics | 959.23 Mn | 948.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 17.78 Mn |
| Dec 31, 2021 | 17.78 Mn |
| Dec 31, 2020 | 214,000.00 |
| Dec 31, 2020 | 214,000.00 |
| Sep 30, 2020 | 3.13 Mn |
| Sep 30, 2020 | 3.13 Mn |
| Jun 30, 2020 | 418,096.00 |
| Jun 30, 2020 | 418,096.00 |
| Mar 31, 2020 | 3.70 Mn |
| Mar 31, 2020 | 3.70 Mn |
| Dec 31, 2019 | -975,000.00 |
| Dec 31, 2019 | -975,000.00 |
| Jun 30, 2019 | -157,000.00 |
| Jun 30, 2019 | -157,000.00 |
| Mar 31, 2019 | 157,000.00 |
| Mar 31, 2019 | 157,000.00 |
| Dec 31, 2018 | 488,000.00 |
| Dec 31, 2018 | 488,000.00 |
| Dec 31, 2017 | 1.22 Mn |
| Dec 31, 2017 | 1.22 Mn |